Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Journal of the American College of Cardiology

Volumn 68, Issue 10, 2016, Pages 1116-1139

  Bittl, John A ^a   Baber, Usman ^a   Bradley, Steven M ^a   Wijeysundera, Duminda N ^a  

^a NONE

Author keywords

ACC Scientific Statements; acute coronary syndrome; aspirin; coronary artery disease; coronary stents; dual antiplatelet therapy (DAPT); focused update; P2Y12 inhibitor; stable ischemic heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO; TICAGRELOR;

ADVERSE OUTCOME; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; INCIDENCE; LONG TERM CARE; MORTALITY RATE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROBABILITY; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPARATIVE STUDY; HEMORRHAGE; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOSIS; TIME FACTOR;

CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS; TIME FACTORS;

EID: 84994022930     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.03.512     Document Type: Article

References (72)

1. 1 Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guidelines for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
2. 2 Mehta, S.R., Yusuf, S., Peters, R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
3. 3 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
4. 4 Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
5. 5 Grines, C.L., Bonow, R.O., Casey, D.E. Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 (2007), 813–818.
6. 6 Eisenstein, E.L., Anstrom, K.J., Kong, D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007), 159–168.
7. 7 Pfisterer, M., Brunner-La Rocca, H.P., Buser, P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006), 2584–2591.
8. 8 Palmerini, T., Biondi-Zoccai, G., Della Riva, D., et al. Clinical outcomes with bioabsorbable polymer versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 63 (2014), 299–307.
9. 9 Baber, U., Mehran, R., Sharma, S.K., et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 58 (2011), 1569–1577.
10. 10 Camenzind, E., Wijns, W., Mauri, L., et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 380 (2012), 1396–1405.
11. 11 Mauri, L., Hsieh, W.H., Massaro, J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007), 1020–1029.
12. 12 Park, S.-J., Park, D.-W., Kim, Y.-H., et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362 (2010), 1374–1382.
13. 13 Lee, C.W., Ahn, J.-M., Park, D.-W., et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 129 (2014), 304–312.
14. 14 Valgimigli, M., Campo, G., Monti, M., et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
15. 15 Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 385 (2015), 2371–2382.
16. 16 Gwon, H.-C., Hahn, J.-Y., Park, K.W., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
17. 17 Kim, B.-K., Hong, M.-K., Shin, D.-H., et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60 (2012), 1340–1348.
18. 18 Feres, F., Costa, R.A., Abizaid, A., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
19. 19 Collet, J.-P., Silvain, J., Barthélémy, O., et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384 (2014), 1577–1585.
20. 20 Colombo, A., Chieffo, A., Frasheri, A., et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64 (2014), 2086–2097.
21. 21 Gilard, M., Barragan, P., Noryani, A.A.L., et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 65 (2015), 777–786.
22. 22 Schulz-Schüpke, S., Byrne, R.A., ten Berg, J.M., et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 36 (2015), 1252–1263.
23. 23 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual-antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
24. 24 Helft, G., Steg, P.G., Le Feuvre, C., et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J 37 (2016), 365–374.
25. 25 Bonaca, M.P., Bhatt, D.L., Cohen, M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
26. 26 Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. 2011, National Academies Press, Washington, DC.
27. 27 Jacobs, A.K., Kushner, F.G., Ettinger, S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 213–265.
28. 28 Spiegelhalter, D.J., Abrams, K.R., Myles, J.P., Bayesian Approaches to Clinical Trials and Health Care Evaluations. 2004, Wiley, Hoboken, NJ.
29. 29 Kereiakes, D.J., Yeh, R.W., Massaro, J.M., et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the Dual Antiplatelet Therapy randomized clinical trial. JAMA 313 (2015), 1113–1121.
30. 30 He, Y., Bittl, J.A., Wouhib, A., et al. Case study in cardiovascular medicine: unprotected left main coronary artery disease. Biondi-Zoccai, G., (eds.) Network Meta-Analysis: Evidence Synthesis With Mixed Treatment Comparison, 2014, Nova Science Publishers, Inc., Hauppauge, NY, 285–386.
31. 31 Carlin, B.P., Louis, T.A., Carlin, B.P., Bayesian Methods for Data Analysis. 3rd ed., 2009, CRC Press, Boca Raton, FL.
32. 32 Kruschke, J.K., Doing Bayesian Data Analysis: A Tutorial With R and BUGS. 2010, Academic Press, Burlington, MA.
33. 33 Bhatt, D.L., Flather, M.D., Hacke, W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007), 1982–1988.
34. 34 Schwarzer G.Package ‘meta’. Freiburg, Germany: version 3.8-0, 2012.
35. 35 Lunn, D., Jackson, C., Best, N., et al. The BUGS Book: A Practical Introduction to Bayesian Analysis. 2013, CRC Press, Taylor & Francis Group, Boca Raton, FL.
36. 36 Thomas, A., O'Hara, B., Ligges, U., et al. Making BUGS open. R News, 2006, 12–17.
37. 37 Cates, C.J., Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol 2 (2002), 1–4.
38. 38 Bittl, J.A., Dual-antiplatelet therapy for diabetic patients after stent implantation: lessons from an observational study. J Am Coll Cardiol 66 (2015), 1102–1104.
39. 39 Collet, J.-P., Cuisset, T., Rangé, G., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367 (2012), 2100–2109.
40. 40 The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation 89 (1994), 2892–2907.
41. 41 Piantadosi, S., Stopping considerations. Clinical Trials: A Methodologic Perspective, 1997, Wiley-Interscience, New York, NY, 230–269.
42. 42 Bhatt, D.L., Fox, K.A.A., Hacke, W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
43. 43 Yeh, R.W., Kereiakes, D.J., Steg, P.G., et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 65 (2015), 2211–2221.
44. 44 Udell, J.A., Bonaca, M.P., Collet, J.-P., et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 37 (2016), 390–399.
45. 45 Elmariah, S., Mauri, L., Doros, G., et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis (erratum in Lancet. 2015;355;1834). Lancet 385 (2015), 792–798.
46. 46 US Food and Drug Administration. (November 6, 2015) Plavix (clopidogrel): drug safety communication—long-term treatment does not change risk of death. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducs/ucm471531.htm. Accessed February 24, 2016.
47. 47 Moussa, I., Oetgen, M., Roubin, G., et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99 (1999), 2364–2366.
48. 48 Bertrand, M.E., Rupprecht, H.J., Urban, P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102 (2000), 624–629.
49. 49 Steinhubl, S.R., Berger, P.B., Mann, J.T. 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002), 2411–2420.
50. 50 Daemen, J., Wenaweser, P., Tsuchida, K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007), 667–678.
51. 51 Kleiman, N.S., Grabbing the horns of a dilemma: the duration of dual antiplatelet therapy after stent implantation. Circulation 125 (2012), 1967–1970.
52. 52 Pfisterer, M., Kaiser, C., Jeger, R., No one-size-fits-all: a tailored approach to antithrombotic therapy after stent implantation. Circulation 125 (2012), 471–473.
53. 53 Witzenbichler, B., Dual antiplatelet therapy after drug-eluting stent implantation: is it time to slacken the reins?. J Am Coll Cardiol 60 (2012), 1349–1351.
54. 54 Holmes, D.R. Jr., Art and science. J Am Coll Cardiol 64 (2014), 2098–2100.
55. 55 Colombo, A., Chieffo, A., Dual antiplatelet therapy after drug-eluting stents-how long to treat?. N Engl J Med 371 (2014), 2225–2226.
56. 56 Binder, R.K., Lüscher, T.F., Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding?. Eur Heart J 36 (2015), 1207–1211.
57. 57 Keaney, J.F., Balancing the risks and benefits of dual platelet inhibition. N Engl J Med 372 (2015), 1854–1856.
58. 58 Diamond, G.A., Kaul, S., Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol 43 (2004), 1929–1939.
59. 59 Goodman, S.N., Toward evidence-based medical statistics. 1: the P value fallacy. Ann Intern Med 130 (1999), 995–1004.
60. 60 Meinert, C.L., Tonascia, S., Patient follow-up, close-out, and post-trial follow-up. Clinical Trials: Design, Conduct, and Analysis, 1986, Oxford University Press, New York, NY, 159–165.
61. 61 Morey-Vargas, O.L., Zeballos-Palacios, O.L., Gionfriddo, M.R., et al. The hierarchy of evidence. Biondi-Zoccai, G., (eds.) Network Meta-Analysis: Evidence Synthesis With Mixed Treatment Comparison, 2014, Nova Science Publishers, Inc., Hauppauge, NY, 3–20.
62. 62 Spencer, F.A., Prasad, M., Vandvik, P.O., et al. Longer-versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med 163 (2015), 118–126.
63. 63 Navarese, E.P., Andreotti, F., Schulze, V., et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 350, 2015, h1618.
64. 64 Montalescot, G., Brieger, D., Dalby, A.J., et al. Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence. J Am Coll Cardiol 66 (2015), 832–847.
65. 65 Meinert, C.L., Tonascia, S., Questions concerning the design, analysis, and interpretation of clinical trials. Clinical Trials: Design, Conduct, and Analysis, 1986, Oxford University Press, New York, NY, 196–207.
66. 66 Claessen, B.E., Henriques, J.P.S., Jaffer, F.A., et al. Stent thrombosis: a clinical perspective. J Am Coll Cardiol Intv 7 (2014), 1081–1092.
67. 67 Lasala, J.M., Cox, D.A., Dobies, D., et al. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2 (2009), 285–293.
68. 68 Hermiller, J.B., Krucoff, M.W., Kereiakes, D.J., et al. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. J Am Coll Cardiol Intv 9 (2016), 138–147.
69. 69 Davì, G., Patrono, C., Platelet activation and atherothrombosis. N Engl J Med 357 (2007), 2482–2494.
70. 70 Sabatine, M.S., Cannon, C.P., Gibson, C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for mycocardial infarction with ST-segment elevation. N Engl J Med 352 (2005), 1179–1189.
71. 71 Yusuf, S., Zhao, F., Mehta, S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
72. 72 Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130 (2014), e344–e426.